{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:22:55Z","timestamp":1791645775953,"version":"4.3.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA198365"],"award-info":[{"award-number":["CA198365"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA226925"],"award-info":[{"award-number":["CA226925"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["V2016-013"],"award-info":[{"award-number":["V2016-013"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["133887-RSG-19-160-01-TBE"],"award-info":[{"award-number":["133887-RSG-19-160-01-TBE"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The transforming growth factor-\u03b2 (TGF-\u03b2) pathway typically inhibits tumorigenesis but can promote metastasis during cancer progression. Activin receptor-like kinase 4 (ALK4), a type I TGF-\u03b2 family receptor, is frequently downregulated or mutated in cancers, and reduced ALK4 expression correlates with poorer outcomes. However, its role and mechanism of action in cancer progression remains unclear. We demonstrate that ALK4 loss enhances anchorage-independent growth, migration, invasion, and epithelial-mesenchymal transition in vitro, as well as cancer progression in breast and pancreatic cancer models in vivo. Importantly, ALK4 loss promotes canonical TGF-\u03b2 signaling by increasing TGF-\u03b2 receptor N-linked glycosylation and stabilizing these receptors at the cell surface. Mechanistically, ALK4 loss upregulates \u03b21,6 N-acetylglucosaminyltransferase V (MGAT5) and galectin-3, which binds MGAT5-modified glycoproteins to stabilize surface receptors. Consistent with prior observations that galectin-3 preferentially binds to MGAT5-modified glycoproteins to stabilize cell surface receptors like TGF-\u03b2 receptors, we demonstrate that ALK4 loss enhances MGAT5-mediated glycosylation of TGF-\u03b2 receptors, promoting their stabilization and signal transduction. Depleting MGAT5 or inhibiting N-glycosylation effectively suppresses ALK4-loss-induced TGF-\u03b2 signaling and cancer progression.<\/jats:p>","DOI":"10.1038\/s41467-025-67563-1","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:35:21Z","timestamp":1765953321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Loss of ALK4 promotes cancer progression through regulating TGF-\u03b2 receptor N-glycosylation"],"prefix":"10.1038","volume":"17","author":[{"given":"Manqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5601-4519","authenticated-orcid":false,"given":"Mary C.","family":"Leupold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangfeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl A.","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-8702","authenticated-orcid":false,"given":"Christen A.","family":"Khella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushabh N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6796-7791","authenticated-orcid":false,"given":"Michael L.","family":"Gatza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-8901","authenticated-orcid":false,"given":"Gerard C.","family":"Blobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"67563_CR1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrc3500","volume":"13","author":"LM Wakefield","year":"2013","unstructured":"Wakefield, L. M. & Hill, C. S. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 13, 328\u2013341 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"67563_CR2","doi-asserted-by":"crossref","unstructured":"Morikawa, M., Derynck, R. & Miyazono, K. TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology. Cold Spring Harb. Perspect. Biol. 8, a021873, (2016).","DOI":"10.1101\/cshperspect.a021873"},{"key":"67563_CR3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","volume":"19","author":"CJ David","year":"2018","unstructured":"David, C. J. & Massague, J. Contextual determinants of TGFbeta action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419\u2013435 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"67563_CR4","doi-asserted-by":"crossref","unstructured":"Derynck, R. & E. H. Budi, Specificity, versatility, and control of TGF-beta family signaling. Sci. Signal. 12, eaav5183 (2019).","DOI":"10.1126\/scisignal.aav5183"},{"key":"67563_CR5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/dvdy.338","volume":"251","author":"JB Pawlak","year":"2022","unstructured":"Pawlak, J. B. & Blobe, G. C. TGF-beta superfamily co-receptors in cancer. Dev. Dyn. 251, 137\u2013163 (2022).","journal-title":"Dev. Dyn."},{"key":"67563_CR6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","volume":"6","author":"S Liu","year":"2021","unstructured":"Liu, S., Ren, J. & Ten Dijke, P. Targeting TGFbeta signal transduction for cancer therapy. Signal Transduct. Target. Ther. 6, 8 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"67563_CR7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cellsig.2010.01.016","volume":"22","author":"CE Gatza","year":"2010","unstructured":"Gatza, C. E., Oh, S. Y. & Blobe, G. C. Roles for the type III TGF-beta receptor in human cancer. Cell. Signal. 22, 1163\u20131174 (2010).","journal-title":"Cell. Signal."},{"key":"67563_CR8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ceb.2019.07.007","volume":"61","author":"Y Yu","year":"2019","unstructured":"Yu, Y. & Feng, X. H. TGF-beta signaling in cell fate control and cancer. Curr. Opin. Cell Biol. 61, 56\u201363 (2019).","journal-title":"Curr. Opin. Cell Biol."},{"key":"67563_CR9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2005.02.047","volume":"23","author":"RL Elliott","year":"2005","unstructured":"Elliott, R. L. & Blobe, G. C. Role of transforming growth factor Beta in human cancer. J. Clin. Oncol. 23, 2078\u20132093 (2005).","journal-title":"J. Clin. Oncol."},{"key":"67563_CR10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto, M. A. et al. Emt: 2016. Cell 166, 21\u201345 (2016).","journal-title":"Cell"},{"key":"67563_CR11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/cr.2008.316","volume":"19","author":"D Padua","year":"2009","unstructured":"Padua, D. & Massague, J. Roles of TGFbeta in metastasis. Cell Res. 19, 89\u2013102 (2009).","journal-title":"Cell Res."},{"key":"67563_CR12","doi-asserted-by":"crossref","first-page":"786728","DOI":"10.3389\/fcell.2021.786728","volume":"9","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. TGF-beta signaling and resistance to cancer therapy. Front. Cell Dev. Biol. 9, 786728 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"67563_CR13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massague, J. Transforming growth factor-beta signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"67563_CR14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak, S. & Ten Dijke, P. Targeting TGF-beta signaling in cancer. Trends Cancer 3, 56\u201371 (2017).","journal-title":"Trends Cancer"},{"key":"67563_CR15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1158\/1078-0432.CCR-09-1634","volume":"16","author":"Z Zhong","year":"2010","unstructured":"Zhong, Z. et al. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16, 1191\u20131205 (2010).","journal-title":"Clin. Cancer Res."},{"key":"67563_CR16","doi-asserted-by":"crossref","unstructured":"Sanjabi, S., Oh, S. A. & Li, M. O. Regulation of the immune response by TGF-beta: from conception to autoimmunity and infection. Cold Spring Harb. Perspect. Biol. 9, a022236 (2017).","DOI":"10.1101\/cshperspect.a022236"},{"key":"67563_CR17","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.18632\/oncotarget.23795","volume":"9","author":"JM Yingling","year":"2018","unstructured":"Yingling, J. M. et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-beta receptor type I inhibitor. Oncotarget 9, 6659\u20136677 (2018).","journal-title":"Oncotarget"},{"key":"67563_CR18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.1102109","volume":"306","author":"EA Partridge","year":"2004","unstructured":"Partridge, E. A. et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306, 120\u2013124 (2004).","journal-title":"Science"},{"key":"67563_CR19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.2953071","volume":"236","author":"JW Dennis","year":"1987","unstructured":"Dennis, J. W. et al. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236, 582\u2013585 (1987).","journal-title":"Science"},{"key":"67563_CR20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/73163","volume":"6","author":"M Granovsky","year":"2000","unstructured":"Granovsky, M. et al. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat. Med. 6, 306\u2013312 (2000).","journal-title":"Nat. Med."},{"key":"67563_CR21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cell.2007.01.049","volume":"129","author":"KS Lau","year":"2007","unstructured":"Lau, K. S. et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129, 123\u2013134 (2007).","journal-title":"Cell"},{"key":"67563_CR22","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1073\/pnas.051484398","volume":"98","author":"GH Su","year":"2001","unstructured":"Su, G. H. et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc. Natl. Acad. Sci. USA 98, 3254\u20133257 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67563_CR23","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-13-126","volume":"13","author":"Y Togashi","year":"2014","unstructured":"Togashi, Y. et al. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Mol. Cancer 13, 126 (2014).","journal-title":"Mol. Cancer"},{"key":"67563_CR24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nature11114","volume":"486","author":"PA Perez-Mancera","year":"2012","unstructured":"Perez-Mancera, P. A. et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486, 266\u2013270 (2012).","journal-title":"Nature"},{"key":"67563_CR25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2015.09.013","volume":"150","author":"W Qiu","year":"2016","unstructured":"Qiu, W. et al. Loss of activin receptor type 1B accelerates development of intraductal papillary mucinous neoplasms in mice with activated KRAS. Gastroenterology 150, 218\u2013228.e12 (2016).","journal-title":"Gastroenterology"},{"key":"67563_CR26","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1158\/0008-5472.CAN-19-3763","volume":"80","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Oncogene-induced senescence limits the progression of pancreatic neoplasia through production of activin A. Cancer Res. 80, 3359\u20133371 (2020).","journal-title":"Cancer Res."},{"key":"67563_CR27","doi-asserted-by":"crossref","first-page":"15635","DOI":"10.1073\/pnas.1904714116","volume":"116","author":"H Takeda","year":"2019","unstructured":"Takeda, H. et al. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc. Natl. Acad. Sci. USA 116, 15635\u201315644 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67563_CR28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature03799","volume":"436","author":"AJ Minn","year":"2005","unstructured":"Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518\u2013524 (2005).","journal-title":"Nature"},{"key":"67563_CR29","doi-asserted-by":"crossref","first-page":"101387","DOI":"10.1016\/j.jcmgh.2024.101387","volume":"18","author":"K Saeki","year":"2024","unstructured":"Saeki, K. et al. Acvr1b loss increases formation of pancreatic precancerous lesions from acinar and ductal cells of origin. Cell. Mol. Gastroenterol. Hepatol. 18, 101387 (2024).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"67563_CR30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)00121-5","volume":"103","author":"J Massague","year":"2000","unstructured":"Massague, J., Blain, S. W. & Lo, R. S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103, 295\u2013309 (2000).","journal-title":"Cell"},{"key":"67563_CR31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1097-2765(01)00249-0","volume":"7","author":"C Yeo","year":"2001","unstructured":"Yeo, C. & Whitman, M. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol. Cell 7, 949\u2013957 (2001).","journal-title":"Mol. Cell"},{"key":"67563_CR32","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 53, 1334\u20131347 (2021).","journal-title":"Nat. Genet."},{"key":"67563_CR33","doi-asserted-by":"crossref","first-page":"21037","DOI":"10.1074\/jbc.M110.114959","volume":"285","author":"D Sako","year":"2010","unstructured":"Sako, D. et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J. Biol. Chem. 285, 21037\u201321048 (2010).","journal-title":"J. Biol. Chem."},{"key":"67563_CR34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/0092-8674(92)90395-S","volume":"71","author":"JL Wrana","year":"1992","unstructured":"Wrana, J. L. et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71, 1003\u20131014 (1992).","journal-title":"Cell"},{"key":"67563_CR35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ceb.2011.05.001","volume":"23","author":"C Boscher","year":"2011","unstructured":"Boscher, C., Dennis, J. W. & Nabi, I. R. Glycosylation, galectins and cellular signaling. Curr. Opin. Cell Biol. 23, 383\u2013392 (2011).","journal-title":"Curr. Opin. Cell Biol."},{"key":"67563_CR36","doi-asserted-by":"crossref","unstructured":"Gao, Y. et al. Role of glycans on key cell surface receptors that regulate cell proliferation and cell death. Cells 10, 1252 (2021).","DOI":"10.3390\/cells10051252"},{"key":"67563_CR37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/BJ20111923","volume":"445","author":"YW Kim","year":"2012","unstructured":"Kim, Y. W. et al. TGF-beta sensitivity is determined by N-linked glycosylation of the type II TGF-beta receptor. Biochem. J. 445, 403\u2013411 (2012).","journal-title":"Biochem. J."},{"key":"67563_CR38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","volume":"172","author":"NC Henderson","year":"2008","unstructured":"Henderson, N. C. et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172, 288\u2013298 (2008).","journal-title":"Am. J. Pathol."},{"key":"67563_CR39","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/sj.onc.1202124","volume":"17","author":"L Chen","year":"1998","unstructured":"Chen, L. et al. The her-2\/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products. Oncogene 17, 2087\u20132093 (1998).","journal-title":"Oncogene"},{"key":"67563_CR40","doi-asserted-by":"crossref","first-page":"22941","DOI":"10.1074\/jbc.274.33.22941","volume":"274","author":"JH Ko","year":"1999","unstructured":"Ko, J. H. et al. Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines. J. Biol. Chem. 274, 22941\u201322948 (1999).","journal-title":"J. Biol. Chem."},{"key":"67563_CR41","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.tranon.2018.04.008","volume":"11","author":"R Wang","year":"2018","unstructured":"Wang, R. et al. Hydrogen sulfide demonstrates promising antitumor efficacy in gastric carcinoma by targeting MGAT5. Transl. Oncol. 11, 900\u2013910 (2018).","journal-title":"Transl. Oncol."},{"key":"67563_CR42","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nchembio.2194","volume":"12","author":"C Lopez-Sambrooks","year":"2016","unstructured":"Lopez-Sambrooks, C. et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat. Chem. Biol. 12, 1023\u20131030 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"67563_CR43","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2867-14-45","volume":"14","author":"V Chesnokov","year":"2014","unstructured":"Chesnokov, V. et al. Anti-cancer activity of glucosamine through inhibition of N-linked glycosylation. Cancer Cell Int. 14, 45 (2014).","journal-title":"Cancer Cell Int."},{"key":"67563_CR44","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1152\/ajpendo.00275.2016","volume":"312","author":"DR Beriault","year":"2017","unstructured":"Beriault, D. R. et al. Glucosamine induces ER stress by disrupting lipid-linked oligosaccharide biosynthesis and N-linked protein glycosylation. Am. J. Physiol. Endocrinol. Metab. 312, E48\u2013E57 (2017).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"67563_CR45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massague","year":"2012","unstructured":"Massague, J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616\u2013630 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"67563_CR46","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nrc3603","volume":"13","author":"M Pickup","year":"2013","unstructured":"Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 13, 788\u2013799 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"67563_CR47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.15430\/JCP.2020.25.4.213","volume":"25","author":"HJ Lee","year":"2020","unstructured":"Lee, H. J. Recent advances in the development of TGF-beta signaling inhibitors for anticancer therapy. J. Cancer Prev. 25, 213\u2013222 (2020).","journal-title":"J. Cancer Prev."},{"key":"67563_CR48","first-page":"4479","volume":"9","author":"S Herbertz","year":"2015","unstructured":"Herbertz, S. et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des. Dev. Ther. 9, 4479\u20134499 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"67563_CR49","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nm.1943","volume":"15","author":"M Korpal","year":"2009","unstructured":"Korpal, M. et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960\u2013966 (2009).","journal-title":"Nat. Med."},{"key":"67563_CR50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13402-014-0210-8","volume":"38","author":"A Maier","year":"2015","unstructured":"Maier, A. et al. Anti-tumor activity of the TGF-beta receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol. (Dordr.) 38, 131\u2013144 (2015).","journal-title":"Cell Oncol. (Dordr.)"},{"key":"67563_CR51","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916\u2013924 (2011).","journal-title":"Toxicol. Pathol."},{"key":"67563_CR52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/toxsci\/kfaa024","volume":"175","author":"MS Mitra","year":"2020","unstructured":"Mitra, M. S. et al. A potent pan-TGFbeta neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys. Toxicol. Sci. 175, 24\u201334 (2020).","journal-title":"Toxicol. Sci."},{"key":"67563_CR53","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst, R. J. & Hata, A. Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790\u2013811 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"67563_CR54","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1210\/jc.2002-020527","volume":"87","author":"DC Danila","year":"2002","unstructured":"Danila, D. C. et al. Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells. J. Clin. Endocrinol. Metab. 87, 4741\u20134746 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"67563_CR55","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1128\/MCB.16.3.1066","volume":"16","author":"L Attisano","year":"1996","unstructured":"Attisano, L. et al. Activation of signalling by the activin receptor complex. Mol. Cell Biol. 16, 1066\u20131073 (1996).","journal-title":"Mol. Cell Biol."},{"key":"67563_CR56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/153537020222700201","volume":"227","author":"YG Chen","year":"2002","unstructured":"Chen, Y. G. et al. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp. Biol. Med. (Maywood) 227, 75\u201387 (2002).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"67563_CR57","doi-asserted-by":"crossref","unstructured":"Qiu, W. et al. Dual roles of the activin signaling pathway in pancreatic cancer. Biomedicines 9, 821 (2021).","DOI":"10.3390\/biomedicines9070821"},{"key":"67563_CR58","doi-asserted-by":"crossref","DOI":"10.1038\/npjbcancer.2015.7","volume":"1","author":"M Bashir","year":"2015","unstructured":"Bashir, M. et al. Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer. NPJ Breast Cancer 1, 15007 (2015).","journal-title":"NPJ Breast Cancer"},{"key":"67563_CR59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1245\/s10434-007-9631-1","volume":"15","author":"K Yoshinaga","year":"2008","unstructured":"Yoshinaga, K. et al. Activin a causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells. Ann. Surg. Oncol. 15, 96\u2013103 (2008).","journal-title":"Ann. Surg. Oncol."},{"key":"67563_CR60","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1585","volume":"2","author":"M Antsiferova","year":"2011","unstructured":"Antsiferova, M. et al. Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat. Commun. 2, 576 (2011).","journal-title":"Nat. Commun."},{"key":"67563_CR61","doi-asserted-by":"crossref","unstructured":"Hinck, A. P., Mueller, T. D. & Springer, T. A. Structural biology and evolution of the TGF-beta family. Cold Spring Harb. Perspect. Biol. 8, a022103 (2016).","DOI":"10.1101\/cshperspect.a022103"},{"key":"67563_CR62","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1177\/1535370219880894","volume":"244","author":"EJ Goebel","year":"2019","unstructured":"Goebel, E. J. et al. Structural biology of the TGFbeta family. Exp. Biol. Med. (Maywood) 244, 1530\u20131546 (2019).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"67563_CR63","doi-asserted-by":"crossref","first-page":"854284","DOI":"10.3389\/fonc.2022.854284","volume":"12","author":"S Lin","year":"2022","unstructured":"Lin, S. et al. Identification of glycogene signature as a tool to predict the clinical outcome and immunotherapy response in breast cancer. Front. Oncol. 12, 854284 (2022).","journal-title":"Front. Oncol."},{"key":"67563_CR64","doi-asserted-by":"crossref","first-page":"103541","DOI":"10.1016\/j.ebiom.2021.103541","volume":"71","author":"Y Mohamed Abd-El-Halim","year":"2021","unstructured":"Mohamed Abd-El-Halim, Y. et al. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. EBioMedicine 71, 103541 (2021).","journal-title":"EBioMedicine"},{"key":"67563_CR65","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1158\/0008-5472.CAN-20-2642","volume":"81","author":"R Yu","year":"2021","unstructured":"Yu, R. et al. Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching. Cancer Res. 81, 2625\u20132635 (2021).","journal-title":"Cancer Res."},{"key":"67563_CR66","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1541-7786.MCR-17-0120","volume":"15","author":"Z Hassani","year":"2017","unstructured":"Hassani, Z. et al. Phostine PST3.1a Targets MGAT5 and inhibits glioblastoma-initiating cell invasiveness and proliferation. Mol. Cancer Res. 15, 1376\u20131387 (2017).","journal-title":"Mol. Cancer Res."},{"key":"67563_CR67","first-page":"718","volume":"51","author":"B Fernandes","year":"1991","unstructured":"Fernandes, B. et al. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 51, 718\u2013723 (1991).","journal-title":"Cancer Res."},{"key":"67563_CR68","doi-asserted-by":"crossref","unstructured":"de-Souza-Ferreira, M., Ferreira, E. E. & de-Freitas-Junior, J. C. M. Aberrant N-glycosylation in cancer: MGAT5 and beta1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression. Cell. Oncol. (Dordr.) 46, 481\u2013501 (2023).","DOI":"10.1007\/s13402-023-00770-4"},{"key":"67563_CR69","first-page":"1115","volume":"30","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. IGF2BP1 promotes the liver cancer stem cell phenotype by regulating MGAT5 mRNA stability by m6A RNA methylation. Stem Cells Dev. 30, 1115\u20131125 (2021).","journal-title":"Stem Cells Dev."},{"key":"67563_CR70","first-page":"585","volume":"9","author":"G Yan","year":"2019","unstructured":"Yan, G. et al. Decreased miR-124-3p promoted breast cancer proliferation and metastasis by targeting MGAT5. Am. J. Cancer Res. 9, 585\u2013596 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"67563_CR71","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/MCB.26.8.3181-3193.2006","volume":"26","author":"A Lagana","year":"2006","unstructured":"Lagana, A. et al. Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol. Cell. Biol. 26, 3181\u20133193 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"67563_CR72","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/35055582","volume":"409","author":"M Demetriou","year":"2001","unstructured":"Demetriou, M. et al. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409, 733\u2013739 (2001).","journal-title":"Nature"},{"key":"67563_CR73","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2009.12.008","volume":"139","author":"JW Dennis","year":"2009","unstructured":"Dennis, J. W., Nabi, I. R. & Demetriou, M. Metabolism, cell surface organization, and disease. Cell 139, 1229\u20131241 (2009).","journal-title":"Cell"},{"key":"67563_CR74","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1600-0854.2009.00981.x","volume":"10","author":"JW Dennis","year":"2009","unstructured":"Dennis, J. W. et al. Adaptive regulation at the cell surface by N-glycosylation. Traffic 10, 1569\u20131578 (2009).","journal-title":"Traffic"},{"key":"67563_CR75","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/humrep\/dep250","volume":"24","author":"CX Lei","year":"2009","unstructured":"Lei, C. X. et al. Interactions between galectin-3 and integrinbeta3 in regulating endometrial cell proliferation and adhesion. Hum. Reprod. 24, 2879\u20132889 (2009).","journal-title":"Hum. Reprod."},{"key":"67563_CR76","doi-asserted-by":"crossref","first-page":"734346","DOI":"10.3389\/fcell.2021.734346","volume":"9","author":"I Cano","year":"2021","unstructured":"Cano, I. et al. Galectin-3 enhances vascular endothelial growth factor-A receptor 2 activity in the presence of vascular endothelial growth factor. Front. Cell Dev. Biol. 9, 734346 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"67563_CR77","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1210\/mend.14.12.0570","volume":"14","author":"Y Zhou","year":"2000","unstructured":"Zhou, Y. et al. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Mol. Endocrinol. 14, 2066\u20132075 (2000).","journal-title":"Mol. Endocrinol."},{"key":"67563_CR78","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1172\/JCI65745","volume":"123","author":"BA Hanks","year":"2013","unstructured":"Hanks, B. A. et al. Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment. J. Clin. Investig. 123, 3925\u20133940 (2013).","journal-title":"J. Clin. Investig."},{"key":"67563_CR79","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1093\/nar\/18.12.3587","volume":"18","author":"JP Morgenstern","year":"1990","unstructured":"Morgenstern, J. P. & Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587\u20133596 (1990).","journal-title":"Nucleic Acids Res."},{"key":"67563_CR80","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1172\/JCI29293","volume":"117","author":"M Dong","year":"2007","unstructured":"Dong, M. et al. The type III TGF-beta receptor suppresses breast cancer progression. J. Clin. Investig. 117, 206\u2013217 (2007).","journal-title":"J. Clin. Investig."},{"key":"67563_CR81","doi-asserted-by":"crossref","unstructured":"Cvetkovic, D., Goertzen, C. G. & Bhattacharya, M. Quantification of breast cancer cell invasiveness using a three-dimensional (3D) model. J. Vis. Exp. 88, 51341 (2014).","DOI":"10.3791\/51341"},{"key":"67563_CR82","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1096\/fj.201700867RR","volume":"32","author":"H Tian","year":"2018","unstructured":"Tian, H. et al. Endoglin interacts with VEGFR2 to promote angiogenesis. FASEB J. 32, 2934\u20132949 (2018).","journal-title":"FASEB J."},{"key":"67563_CR83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas, N.","year":"2012","unstructured":"Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"67563_CR84","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","volume":"163","author":"G Ciriello","year":"2015","unstructured":"Ciriello, G. et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163, 506\u2013519 (2015).","journal-title":"Cell"},{"key":"67563_CR85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Cancer Genome Atlas Research Network.","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Electronic address, a.a.d.h.e. and N. Cancer Genome Atlas Research, integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203.e13 (2017).","journal-title":"Cancer Cell"},{"key":"67563_CR86","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"67563_CR87","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol."},{"key":"67563_CR88","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","volume":"15","author":"KP Hoeflich","year":"2009","unstructured":"Hoeflich, K. P. et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 15, 4649\u20134664 (2009).","journal-title":"Clin. Cancer Res."},{"key":"67563_CR89","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500\u2013501 (2006).","journal-title":"Nat. Genet."},{"key":"67563_CR90","doi-asserted-by":"crossref","first-page":"D991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett, T. et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 41, D991\u2013D995 (2013).","journal-title":"Nucleic Acids Res."},{"key":"67563_CR91","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","volume":"23","author":"S Davis","year":"2007","unstructured":"Davis, S. & Meltzer, P. S. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 23, 1846\u20131847 (2007).","journal-title":"Bioinformatics"},{"key":"67563_CR92","doi-asserted-by":"crossref","first-page":"e27633","DOI":"10.2196\/27633","volume":"23","author":"A Lanczky","year":"2021","unstructured":"Lanczky, A. & Gyorffy, B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J. Med. Internet Res. 23, e27633 (2021).","journal-title":"J. Med. Internet Res."},{"key":"67563_CR93","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1158\/0008-5472.CAN-15-2841","volume":"76","author":"S Yang","year":"2016","unstructured":"Yang, S. et al. A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2. Cancer Res. 76, 3838\u20133850 (2016).","journal-title":"Cancer Res."},{"key":"67563_CR94","first-page":"Unit 7 1","volume":"Chapter 7","author":"JS Bonifacino","year":"2001","unstructured":"Bonifacino, J. S. Metabolic labeling with amino acids. Curr. Protoc. Cell Biol. Chapter 7, Unit 7 1 (2001).","journal-title":"Curr. Protoc. Cell Biol."},{"key":"67563_CR95","doi-asserted-by":"crossref","unstructured":"Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216\u2013W221 (2022).","DOI":"10.1093\/nar\/gkac194"},{"key":"67563_CR96","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W Huang da","year":"2009","unstructured":"Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67563-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67563-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67563-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:08:10Z","timestamp":1769216890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67563-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67563"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67563-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"854"}}